Viridiflorol is an aromadendrane-type sesquiterpene alcohol found in tea tree, niaouli, cistus, and other essential oils already represented in the AromaForge archive. Compared with many trace sesquiterpenes, it has a modest but real preclinical literature that includes anti-inflammatory, antioxidant, anti-mycobacterial, antifungal, and cytotoxic cell-study signals, plus strong biosynthetic and identity support. That evidence is still preclinical and should not be translated into medical claims, but it is materially stronger than a composition-only profile.
Chemical identity and composition
PubChem resolves viridiflorol to CID 11996452 with formula C15H26O, while Sigma-Aldrich and other analytical suppliers classify it as an aromadendrene sesquiterpenoid. In AromaForge oil records, viridiflorol appears both as a minor marker in tea tree and niaouli profiles and as a major oxygenated sesquiterpene in cistus-type profiles.
Aroma and practical use
- Use the recorded woody, herbal, green, camphoraceous, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 Journal of Ethnopharmacology study evaluated viridiflorol from Allophylus edulis and reported anti-inflammatory, antioxidant, and anti-Mycobacterium tuberculosis activity for the isolated constituent in preclinical testing.
A 2016 Journal of Ethnopharmacology study evaluated viridiflorol from Allophylus edulis and reported anti-inflammatory, antioxidant, and anti-Mycobacterium tuberculosis activity for the isolated constituent in preclinical testing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2022 follow-up study reported potential anti-arthritic, anti-nociceptive, and anti-hyperalgesic effects for viridiflorol in preclinical models.
A 2022 follow-up study reported potential anti-arthritic, anti-nociceptive, and anti-hyperalgesic effects for viridiflorol in preclinical models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 Biomolecules paper on Serendipita indica sesquiterpene synthase reported that viridiflorol inhibited germination of Colletotrichum truncatum spores when added to culture medium.
A 2021 Biomolecules paper on Serendipita indica sesquiterpene synthase reported that viridiflorol inhibited germination of Colletotrichum truncatum spores when added to culture medium.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 in vitro study reported concentration-dependent cytotoxicity and apoptosis-related cell death after viridiflorol exposure in breast, lung, and brain cancer cell lines.
A 2021 in vitro study reported concentration-dependent cytotoxicity and apoptosis-related cell death after viridiflorol exposure in breast, lung, and brain cancer cell lines.
This experimental finding does not establish benefit, dose or safety in people using this blend.
PubChem notes that viridiflorol is a sesquiterpenoid isolated from several plant species and describes it as a strong feeding deterrent for the melaleuca weevil that retards larval development.
PubChem notes that viridiflorol is a sesquiterpenoid isolated from several plant species and describes it as a strong feeding deterrent for the melaleuca weevil that retards larval development.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human dermal limit or standalone IFRA restriction for isolated viridiflorol was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The direct activity literature is preclinical only, so archive copy should avoid implying proven antimicrobial, anti-inflammatory, pain, or anticancer effects in humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
inflammation modulating signal
A mouse-study abstract and title-level follow-up paper support anti-inflammatory and analgesic-like activity for viridiflorol, but the accessible sources did not provide a fully validated human mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
fungal germination inhibition
A fungal biosynthesis paper reported that added viridiflorol inhibited germination of Colletotrichum truncatum spores, supporting a direct antifungal signal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
apoptosis related cytotoxicity
An in vitro study reported concentration-dependent cytotoxicity and apoptosis-related readouts in three cancer cell lines, which is useful mechanistic context but not clinical evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated viridiflorol were verified.
- No standalone constituent-specific dermal ceiling or robust toxicology monograph was confirmed in this pass.
- Most biological evidence remains cell, microbial, or animal level rather than clinical.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.